Details for Patent: 12,290,499

Which drugs does patent 12,290,499 protect, and when does it expire?

Patent 12,290,499 protects VIGAFYDE and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 12,290,499

Title:	Vigabatrin liquid pharmaceutical composition
Abstract:	The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.
Inventor(s):	Nrupa Patel, Raenel V. Gibson, Michael M. Smith, Edwin Urrutia
Assignee:	Pyros Pharmaceuticals Inc
Application Number:	US18/759,349
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 12,290,499

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pyros Pharms	VIGAFYDE	vigabatrin	SOLUTION;ORAL	217684-001	Jun 17, 2024		RX	Yes	Yes	12,290,499		Y

International Family Members for US Patent 12,290,499

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
World Intellectual Property Organization (WIPO)	2024058812